Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment

• Published in: Osteoarthritis and cartilage 2019-09, Vol.27 (9), p.1347-1360
• Main Authors: Deshmukh, V., O'Green, A.L., Bossard, C., Seo, T., Lamangan, L., Ibanez, M., Ghias, A., Lai, C., Do, L., Cho, S., Cahiwat, J., Chiu, K., Pedraza, M., Anderson, S., Harris, R., Dellamary, L., KC, S., Barroga, C., Melchior, B., Tam, B., Kennedy, S., Tambiah, J., Hood, J., Yazici, Y.
• Format: Article
• Language: English
• Subjects: Animals; Anti-Inflammatory Agents - therapeutic use; Blotting, Western; Cells, Cultured; Chondrocyte; CLK2; Disease Models, Animal; Dyrk Kinases; DYRK1A; Humans; Imidazoles - therapeutic use; Indazoles - therapeutic use; Lorecivivint; Osteoarthritis; Osteoarthritis, Knee - drug therapy; Polymerase Chain Reaction; Protein Serine-Threonine Kinases - antagonists & inhibitors; Protein-Tyrosine Kinases - antagonists & inhibitors; Pyridines - therapeutic use; Rats; SM04690; Wnt pathway; Wnt Signaling Pathway - drug effects
• ISSN: 1063-4584; 1522-9653
• DOI: 10.1016/j.joca.2019.05.006

Wnt pathway upregulation contributes to knee osteoarthritis (OA) through osteoblast differentiation, increased catabolic enzymes, and inflammation. The small-molecule Wnt pathway inhibitor, lorecivivint (SM04690), which previously demonstrated chondrogenesis and cartilage protection in an animal OA model, was evaluated to elucidate its mechanism of action. Biochemical assays measured kinase activity. Western blots measured protein phosphorylation in human mesenchymal stem cells (hMSCs), chondrocytes, and synovial fibroblasts. siRNA knockdown effects in hMSCs and BEAS-2B cells on Wnt pathway, chondrogenic genes, and LPS-induced inflammatory cytokines was measured by qPCR. In vivo anti-inflammation, pain, and function were evaluated following single intra-articular (IA) lorecivivint or vehicle injection in the monosodium iodoacetate (MIA)-induced rat OA model. Lorecivivint inhibited intranuclear kinases CDC-like kinase 2 (CLK2) and dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A). Lorecivivint inhibited CLK2-mediated phosphorylation of serine/arginine-rich (SR) splicing factors and DYRK1A-mediated phosphorylation of SIRT1 and FOXO1. siRNA knockdowns identified a role for CLK2 and DYRK1A in Wnt pathway modulation without affecting β-catenin with CLK2 inhibition inducing early chondrogenesis and DYRK1A inhibition enhancing mature chondrocyte function. NF-κB and STAT3 inhibition by lorecivivint reduced inflammation. DYRK1A knockdown was sufficient for anti-inflammatory effects, while combined DYRK1A/CLK2 knockdown enhanced this effect. In the MIA model, lorecivivint inhibited production of inflammatory cytokines and cartilage degradative enzymes, resulting in increased joint cartilage, decreased pain, and improved weight-bearing function. Lorecivivint inhibition of CLK2 and DYRK1A suggested a novel mechanism for Wnt pathway inhibition, enhancing chondrogenesis, chondrocyte function, and anti-inflammation. Lorecivivint shows potential to modify structure and improve symptoms of knee OA.